89bio, Inc. Common Stock

ETNB XNAS • PHARMACEUTICAL PREPARATIONS

Historical Short Interest Share

Chase Ink Business Preferred®

Earn Up to 150K Bonus Points

Transfer points to 14+ airline & hotel partners. Up to 40% upgrade value on first class travel. $95/yr.

Apply Now

Market Cap

2.2B

Short interest (Oct 15)

4.6%

Net Short (Oct 29 ): -2.0%

Borrow Fee

0.53%

Available Shares

Price Chart

Company Overview

89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin (previously BIO89-100), a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).

Company Info

Exchange: NASDAQ

Industry: PHARMACEUTICAL PREPARATIONS

CIK: 0001785173

Asset Type: CS

Market Data

Market Cap: $2,203,627,631

Employees: 93

Status: Active

Short Interest

Current Borrow Fee 0.53%

Range: 0.53% - 0.53%

Available Shares 0

Range: 0 - 0

Recent Changes

Quick Actions

View Dilution Chart

Add to Watchlist Set Price Alert View Options Chain

Investment Risk

This is not financial advice. All investments carry risk. Do your own research before making investment decisions.

Weekly Research

Get Weekly Super Stonk Alerts

Never miss a squeeze opportunity. Get our weekly analysis of high short interest stocks, AI-discovered gems, and dilution warnings delivered to your inbox.

No spam • Unsubscribe anytime